Thromboendarterectomy for Chronic Thromboembolic Pulmonary Hypertension: Insights from histopathological findings of surgical specimens

The pathophysiology of chronic thromboembolic pulmonary hypertension is uncertain. Although thromboendarterectomy has become a common treatment modality, few reports have examined characteristics of surgical thromboendarterectomy specimens with respect to pre-endarterectomy pulmonary artery pressures. We hypothesized that comprehensive clinicopathologic review of specimens at our chronic thromboembolic pulmonary hypertension surgical referral center may provide pathophysiologic insight into this disorder. We reviewed clinical and histopathologic features of patients who underwent pulmonary thromboendarterectomy for chronic thromboembolic pulmonary hypertension at the Massachusetts General Hospital from 2010-2013. A panel of histochemical and immunohistochemical stains was applied. We examined the thromboendarterectomy specimens of 22 women and 20 men (mean age 55 years, range 30-78) who had pulmonary arterial pressures determined by right heart catheterization. 19 patients (45%) had a documented history of deep venous thrombosis. Other comorbid conditions included autoimmune diseases and various cardiopulmonary disorders. Histological examination revealed variably organized pulmonary thrombi, neovascularization, intimal hyperplasia with associated elastic reduplication, medial calcification and increased medial smooth muscle. Thromboendarterectomy specimens that included diffusely organized thrombi were larger than those with acute thrombus or focal organization (p=0.016). Atheromatous change was associated with higher pre-operative mean pulmonary arterial pressures (53 vs. 45 mm Hg, p=0.04). These results suggest that vascular remodeling may be a critical hemodynamic factor in chronic thromboembolic pulmonary hypertension. Correspondence to: Alexandra E. Kovach, Department of Pathology, Microbiology and Immunology, Vanderbilt University School of Medicine, 11236 Doctors’ Office Tower, Box 3-9065, 2200 Children’s Way, Nashville, TN 37232-9065, Tel: 615-936-2879; Fax: 615-936-7828; E-mail: alexandra.kovach@vanderbilt.edu

[1]  S. Rosenkranz Pulmonary hypertension 2015: current definitions, terminology, and novel treatment options , 2015, Clinical Research in Cardiology.

[2]  M. Toshner,et al.  Chronic thromboembolic pulmonary hypertension: time for research in pathophysiology to catch up with developments in treatment , 2014, F1000prime reports.

[3]  TITLE : Drug Therapy for Chronic Thromboembolic Pulmonary Hypertension : A Review of the Comparative Clinical Effectiveness , 2014 .

[4]  T. Morris,et al.  Chronic thromboembolic pulmonary hypertension-associated dysfibrinogenemias exhibit disorganized fibrin structure. , 2013, Thrombosis research.

[5]  Jie Liu,et al.  The distinguishing cellular features of pulmonary artery smooth muscle cells from chronic thromboembolic pulmonary hypertension patients , 2013, Experimental lung research.

[6]  J. Yuan,et al.  MicroRNA Expression Profile of Pulmonary Artery Smooth Muscle Cells and the Effect of Let-7d in Chronic Thromboembolic Pulmonary Hypertension , 2013, Pulmonary circulation.

[7]  Lan Zhao,et al.  Fibrinogen Aα Thr312Ala Polymorphism Specifically Contributes to Chronic Thromboembolic Pulmonary Hypertension by Increasing Fibrin Resistance , 2013, PloS one.

[8]  S. Sakao,et al.  Crosstalk between endothelial cell and thrombus in chronic thromboembolic pulmonary hypertension: perspective. , 2013, Histology and histopathology.

[9]  E. Fadel,et al.  Chronic thromboembolic pulmonary hypertension: animal models , 2013, European Respiratory Journal.

[10]  Horst Olschewski,et al.  Updated clinical classification of pulmonary hypertension. , 2009, Journal of the American College of Cardiology.

[11]  I. Yoshino,et al.  Characterization of myofibroblasts in chronic thromboembolic pulmonary hypertension. , 2012, International journal of cardiology.

[12]  M. Madani,et al.  Pulmonary endarterectomy: recent changes in a single institution's experience of more than 2,700 patients. , 2012, The Annals of thoracic surgery.

[13]  J. Yuan,et al.  Risk factors and basic mechanisms of chronic thromboembolic pulmonary hypertension: a current understanding , 2012, European Respiratory Journal.

[14]  W. Klepetko,et al.  Surgical management and outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry. , 2011, The Journal of thoracic and cardiovascular surgery.

[15]  A. Ogawa,et al.  Multipotent mesenchymal progenitor cells are present in endarterectomized tissues from patients with chronic thromboembolic pulmonary hypertension. , 2010, American journal of physiology. Cell physiology.

[16]  Virgil L. Woods,et al.  High prevalence of dysfibrinogenemia among patients with chronic thromboembolic pulmonary hypertension. , 2009, Blood.

[17]  P. Thistlethwaite,et al.  Identification of putative endothelial progenitor cells (CD34+CD133+Flk-1+) in endarterectomized tissue of patients with chronic thromboembolic pulmonary hypertension. , 2009, American journal of physiology. Lung cellular and molecular physiology.

[18]  W. Auger,et al.  Chronic thromboembolic pulmonary hypertension. , 2009, Seminars in respiratory and critical care medicine.

[19]  D. Freed,et al.  Functional and haemodynamic outcome 1 year after pulmonary thromboendarterectomy. , 2008, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[20]  J. Catravas,et al.  Pulmonary capillary endothelial metabolic function in chronic thromboembolic pulmonary hypertension , 2008, Journal of thrombosis and haemostasis : JTH.

[21]  E. Yi,et al.  Pulmonary thromboendarterectomy: a clinicopathologic study of 200 consecutive pulmonary thromboendarterectomy cases in one institution. , 2007, Human pathology.

[22]  M. Wendl This is an Open Access article distribut... , 2007 .

[23]  W. Ageno,et al.  Incidence of chronic thromboembolic pulmonary hypertension after a first episode of pulmonary embolism. , 2006, Chest.

[24]  Paolo Prandoni,et al.  Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. , 2004, The New England journal of medicine.

[25]  W. Edwards,et al.  Surgical pathology of pulmonary thromboendarterectomy: a study of 54 cases from 1990 to 2001. , 2003, Human pathology.

[26]  G. Maurer,et al.  High prevalence of elevated clotting factor VIII in chronic thromboembolic pulmonary hypertension , 2003, Thrombosis and Haemostasis.

[27]  K. Matsushima,et al.  Plasma monocyte chemoattractant protein-1 and pulmonary vascular resistance in chronic thromboembolic pulmonary hypertension. , 2001, American journal of respiratory and critical care medicine.

[28]  P. Friedman,et al.  Distribution of obstructive intimal lesions and their cellular phenotypes in chronic pulmonary hypertension. A morphometric and immunohistochemical study. , 2000, American journal of respiratory and critical care medicine.

[29]  H. C. Stary,et al.  Natural history and histological classification of atherosclerotic lesions: an update. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[30]  Rogers Spencer's pathology of the lung , 1999, Histopathology.

[31]  R. Kradin,et al.  Interferon-gamma and tumor necrosis factor-alpha promote the binding of dendritic cells to fibronectin. , 1994, Pathobiology : journal of immunopathology, molecular and cellular biology.